Profound Medical Corp. (TSE:PRN) Senior Officer Thomas Michael Tamberrino Buys 12,000 Shares

Profound Medical Corp. (TSE:PRN) Senior Officer Thomas Michael Tamberrino bought 12,000 shares of the business’s stock in a transaction that occurred on Thursday, May 15th. The stock was purchased at an average price of C$5.80 per share, for a total transaction of C$69,541.92.

Profound Medical Price Performance

Shares of PRN opened at C$6.63 on Monday. Profound Medical Corp. has a 12-month low of C$5.58 and a 12-month high of C$15.75. The business’s fifty day moving average is C$7.48 and its 200 day moving average is C$9.38. The company has a quick ratio of 14.98, a current ratio of 6.12 and a debt-to-equity ratio of 20.05. The stock has a market cap of C$15.45 million, a P/E ratio of -3.44 and a beta of 1.22.

Wall Street Analysts Forecast Growth

Separately, Raymond James cut Profound Medical from a “strong-buy” rating to a “moderate buy” rating in a report on Friday, May 9th.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.